Does Capital BlueCross cover Zepbound?

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
• BMI of 23 or higher for patients of Asian descent

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• BMI documentation meeting threshold (>= 30 kg/m2 for obesity, or >= 27 kg/m2 for overweight with comorbidity)
• Documentation of weight-related comorbidity if BMI 27-29.9 kg/m2
• For continuation: documentation of >= 5% weight loss after 12 weeks at therapeutic dose

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended

Policy note: Available as subcutaneous injection solution (vial) and Kwikpen formulations. Indicated for adults only (age >= 18) for weight loss. The Asian BMI threshold of >= 23 kg/m2 is noted in the clinical rationale for South Asian, Southeast Asian, and East Asian adults. Efficacy should be assessed after 12 weeks at a therapeutic dose; continuation recommended only for patients achieving >= 5% weight loss.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Pa policy

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of moderate to severe OSA (AHI or REI >= 15 events/hour, or equivalent RDI)
• OSA diagnostic test result: polysomnography (PSG) preferred, or home sleep apnea test (HSAT) with technically adequate device
• BMI documentation >= 30 kg/m2 (obesity)
• If HSAT result is negative, inconclusive, or technically inadequate: PSG results required
• Documentation confirming OSA is not predominantly central or mixed (< 50% central or mixed apneas/hypopneas)

Not covered when

• Craniofacial abnormalities affecting respiration
• Predominantly central or mixed sleep apnea (>= 50% central or mixed apneas/hypopneas)
• Cheyne-Stokes respiration
• Obesity hypoventilation syndrome
• Evidence of daytime hypercapnia
• Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended

Policy note: FDA-approved for moderate to severe OSA in adults with obesity. The SURMOUNT-OSA program (two phase 3 trials) enrolled participants with mean AHIs of ~50 events/hour and mean BMIs ~39 kg/m2. Trial 1 enrolled participants NOT receiving PAP therapy; Trial 2 enrolled participants already on PAP therapy — indicating PAP trial is NOT required for eligibility. OSA severity grading uses AHI (PSG-derived, preferred), REI (HSAT-based surrogate), or RDI (broader physiologic assessment). The 'moderate to severe' OSA threshold per AASM standards is AHI/REI >= 15 events/hour; the document does not explicitly state a numeric threshold in the criteria section but the FDA indication and SURMOUNT-OSA trial context supports >= 15 as the qualifying threshold. Hypopnea scoring per AASM recommended rule: >= 30% airflow reduction >= 10 seconds with >= 3% O2 desaturation and/or arousal.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Pa policy